Precigen shares are trading higher after the company announced FDA confirmation that the ongoing Phase 1/2 study of PRGN-2012 AdenoVerse Immunotherapy will serve as the pivotal study to support accelerated approva.
Portfolio Pulse from Benzinga Newsdesk
Precigen announced that the FDA has confirmed that the ongoing Phase 1/2 study of PRGN-2012 AdenoVerse Immunotherapy will serve as the pivotal study to support accelerated approval. This news has led to a rise in Precigen's share prices.
August 10, 2023 | 4:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Precigen's shares are trading higher after the FDA confirmed that the ongoing Phase 1/2 study of PRGN-2012 AdenoVerse Immunotherapy will serve as the pivotal study for accelerated approval.
The FDA's confirmation of Precigen's ongoing study as the pivotal study for accelerated approval is a positive development for the company. This news indicates progress in the company's drug development process, which is likely to boost investor confidence and drive up the company's share prices in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100